Paradigm Biocapital Advisors LP Viridian Therapeutics, Inc.\De Transaction History

Paradigm Biocapital Advisors LP

$3.1 Billion
Q3 2025

A detailed history of Paradigm Biocapital Advisors LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,609,353 shares of VRDN stock, worth $75 Million. This represents 1.81% of its overall portfolio holdings.

Number of Shares

2,609,353

Previous 2,741,576 4.82%

Holding current value

$75 Million

Previous $38.3 Million 46.44%

% of portfolio

1.81%

Previous 1.79%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$14.5 - $21.61 $1.92 Million - $2.86 Million	-132,223 Reduced 4.82%	2,609,353 $56.1 Million
Q2 2025 Aug 14, 2025	BUY	$11.02 - $16.09 $7.12 Million - $10.4 Million	646,497 Added 30.86%	2,741,576 $38.3 Million
Q1 2025 May 15, 2025	BUY	$13.48 - $20.91 $3.71 Million - $5.75 Million	275,000 Added 15.11%	2,095,079 $28.2 Million
Q4 2024 Feb 14, 2025	SELL	$17.85 - $25.71 $19.2 Million - $27.7 Million	-1,075,610 Reduced 37.15%	1,820,079 $34.9 Million
Q3 2024 Nov 14, 2024	SELL	$12.16 - $23.33 $8,025 - $15,397	-660 Reduced 0.02%	2,895,689 $65.9 Million

Q2 2024 Aug 14, 2024	SELL	$11.6 - $17.26 $24.8 Million - $36.9 Million	-2,135,071 Reduced 42.43%	2,896,349 $37.7 Million
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $4.05 Million - $5.64 Million	236,932 Added 4.94%	5,031,420 $88.1 Million
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $12.4 Million - $25 Million	1,112,741 Added 30.22%	4,794,488 $104 Million
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $19.2 Million - $31.3 Million	1,266,491 Added 52.44%	3,681,747 $56.5 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $7.44 Million - $9.78 Million	329,558 Added 15.8%	2,415,256 $57.5 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $8.38 Million - $12.6 Million	334,531 Added 19.1%	2,085,698 $53.1 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $2.16 Million - $3.42 Million	114,956 Added 7.03%	1,751,167 $51.2 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $3.53 Million - $8.41 Million	329,642 Added 25.23%	1,636,211 $33.6 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $482,446 - $959,842	50,518 Added 4.02%	1,306,569 $15.1 Million
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $789,130 - $981,360	47,000 Added 3.89%	1,256,051 $23.2 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $18.9 Million - $26 Million	1,209,051 New	1,209,051 $23.9 Million

Others Institutions Holding VRDN

# of Institutions

184

Shares Held

81.6M

Call Options Held

39.6K

Put Options Held

94.3K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $1.15B
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.

Account

Paradigm Biocapital Advisors LP Viridian Therapeutics, Inc.\De Transaction History